Viewing Study NCT03579966

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:36 PM
Ignite Modification Date: 2026-02-11 @ 2:37 AM
Study NCT ID: NCT03579966
Status: TERMINATED
Last Update Posted: 2024-05-07
First Post: 2018-06-05
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Sponsor: Catalyst Pharmaceuticals, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myasthenia Gravis, MuSK View
None AChR Myasthenia Gravis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Amifampridine Phosphate Amifampridine View
None 3,4-Diaminopyridine Phosphate View
None 3,4-Diaminopyridine View
None 3,4-DAP View
None Firdapse® View
None Myasthenia Gravis View
None MuSK View
None AChR View